Formulation
OwnerDavid Buell Goodaleinventor
Life of this patent
Estimating the term…
Abstract
The invention relates to sterile pharmaceutical compositions for parenteral administration which comprise an oil-in-water emulsion in which a free radical scavenging sedative agent dissolved in an omega-3 rich water-immiscible solvent, is emulsified with water and stabilised by means of a surfactant, the composition being suitable either directly or after dilution with a liquid diluent for parenteral administration to a warm-blooded animal; in particular to such compositions comprising propofol, and which optionally further comprise a metal ion chelating agent (such as edetate), and the use of such compositions in improving survival in critically ill patients.
Claims25
A sterile pharmaceutical composition for parenteral administration which comprises an oil-in-water emulsion in which a free radical scavenging sedative agent dissolved in an omega-3 rich water-immiscible solvent, is emulsified with water and stabilised by means of a surfactant, the composition being suitable either directly or after dilution with a liquid diluent for parenteral administration to a warm-blooded animal.
A sterile pharmaceutical composition in the form of an oil-in-water emulsion which comprises:
- (a) 1% by weight of propofol,
- (b) 10% by weight of omega-3 rich water-immiscible solvent,
- (c) 1.2% by weight of egg phosphatide,
- (d) 2.25% by weight of glycerol,
- (e) sodium hydroxide,
- (f) water.
A sterile pharmaceutical composition in the form of an oil-in-water emulsion which comprises:
- (a) 2% by weight of propofol,
- (b) 10% by weight of omega-3 rich water-immiscible solvent,
- (c). 1.2% by weight of egg phosphatide,
- (d) 2.25% by weight of glycerol,
- (e) sodium hydroxide,
- (f) water.
A sterile pharmaceutical composition for parenteral administration, which composition comprises an oil-in-water emulsion in which propofol dissolved in an omega-3 rich water-immiscible solvent, is emulsified with water and stabilised by means of a surfactant, and which optionally further comprises a metal ion chelating agent, for use as a medicament for improving survival in a critically ill patient.
The use of a sterile pharmaceutical composition which comprises an oil-in-water emulsion in which propofol dissolved in an omega-3 rich water-immiscible solvent, is emulsified with water and stabilised by means of a surfactant, and which optionally further comprises a metal ion chelating agent, for the manufacture of a medicament for improving survival in a critically ill patient.
A method for improving survival in a critically ill patient which comprises administration to such patient of an effective amount of a sterile pharmaceutical composition which comprises an oil-in-water emulsion in which propofol dissolved in an omega-3 rich water-immiscible solvent, is emulsified with water and is stabilised by means of a surfactant, and which optionally further comprises a metal ion chelating agent.
Dependencies are inferred from the claim text.